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Fatty acid amide hydrolase (FAAH) is a serine hydrolase that catalyzes the deactivating hydrolysis of endocannabinoids. Endogenous FAAH substrates such as anandamide serve as key 
regulatory functions in the body and have been implicated in a variety of pathological conditions including pain, inflammation, sleep disorders, anxiety, depression and vascular hypertension, 
and there has been an increasing interest in the development of inhibitors of this enzyme. Recently, we have reported the binding mode in the FAAH rat structure of the two enantiomers of Flu-
AM1 and Ibu-AM5[1]. Replacing isobutyl group of Ibu-AM5 with a trifluoromethylpyridinylamino moiety led to TPA5, which maintains the FAAH inhibitory activity. Here we investigate 
FAAH inhibition by TPA5 derivatives through computational methods, enzyme kinetics and SAR studies. 
Design and Synthesis 
IC50 = 0.52µM 
Figure 1. Ibu-AM5 FAAH inhibitory activity and TPA series design.	  	  
The 2-arylpropionamides TPA 5-40 were prepared 
by an effective multistep synthesis. 
Computational studies  
Docking were performed on the 
monomer of FAAH X-ray rat with 
Autodock 4.2 centring the box on the 
binding site of AEA (Fig. 2, violet 
spheres) the endogenous substrate of 
FAAH. The results showed that TPA5 
binds to the cavity experimentally 
found for other competitive ligands, 
[2,3] adopting up to four different 
arrangements.  
All-atom molecular dynamics (MD) 
refining of 100 ns were performed on 
each system using Amber12. Free 
energy calculations (MM/GBSA, MM/
PBSA and SIE) and QM/MM were 
used to analyse the stability of the last 
5 ns of the trajectories.  
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Figure 2. 3D structure and localization of FAAH and representation of the 
principal structural features: catalytic residues (cyan sticks), membrane 
interacting helices α18-α19 (orange cartoon) and anandamide analogue (violet 
spheres). 
Docking scores, MD convergence and estimation of binding affinity strongly indicated 
the A1-binding mode as the preferred pose (Table 1).  
TPA5 resulted a competitive inhibitor (Fig. 
3B), showing little dependency upon 
preincubation time, which suggests a 
reversible inhibition (Fig. 3A). 
Mode of inhibition 
Figure 3. Mode of inhibition of rat brain FAAH by TPA5. Panel A: 
homogenates were preincubated with the compounds for the times shown 
prior to addition of 0.5 µM [3H]AEA and assay for FAAH activity (means 
and s.e.m., n=3-4) Panel B: AEA hydrolysis at the substrate and inhibitor 
concentrations shown (means and s.e.m, n=3). 
TPA5 resulted tightly packed between the 
catalytic triad and the ABP channel 
through a series of hydrogen bonds (Fig. 
4A) and hydrophobic interactions with the 
apolar gorge of ABP  (Fig. 4B). The 
methylpyridine moiety adopted a specific 
conformation, which seems a key 
requisite for FAAH inhibition for this 
class of compounds.  
SAR on TPA5 derivatives supported A1-
binding mode. In fact, the introduction of 
a methylene linker (TPA8, TPA9) avoid 
t h e r i g h t c o n f o r m a t i o n o f t h e 
methylpyridine moiety. Similarly, the 
absence or different position of the methyl 
group on the amidopyridine drop off the 
activity. (TPA11-13). Finally, TPA19 
indicated that there is no space to 
accommodate larger groups. 
Table 1. Free energy 
calculation of the 
representative binding 
m o d e s  r e f i n e d 
through MD runs of 
100 ns. A1 mode  
showed convergence 
between monomers. 
In the cases of non-
convergent binding 
m o d e ,  d a t a a r e 
reported  for the best 
c l u s t e r  i n  t h e 
monomer A (a0) and 
B (b0). MMPBSA, 
MMGBSA, SIE and 
QM/MM free energy 
values are in kcal/
mol. 
The replacement of the methyl group in 
the amidopyridine ring by halogens 
(TPA24-27) increased the inhibitory 
activity. In particular, TPA27 showed a 
10-fold enhancement in potency, but with 
a different mode of inhibition.   
Thermodynamic integration calculations were performed to study the effect of chlorine 
substitution, analysing the transformation of the methyl group on TPA5 in the chlorine 
atom in TPA27 and yielded a free energy difference of 0.3 kcal/mol. This result 
indicates a decrease of the TPA27 affinity for the competitive binding site, in 
agreement with the experimental finding that TPA27 follows essentially a non-
competitive inhibition mechanism. 
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Figure 5. Mode of inhibition of rat brain FAAH by TPA27. A) 
homogenates were preincubated with the compounds for the times shown 
prior to addition of 0.5 µM [3H]AEA and assay for FAAH activity (means 
and s.e.m., n=3-4). B) AEA hydrolysis at the substrate and inhibitor 
concentrations shown (means and s.e.m, n=3). C) dilution experiments. 
Inhibition kinetics experiments showed that 
TPA27, unlike TPA5, behaves as non-
competitive inhibitor. Dilution experiments 
(Fig. 5C) revealed that TPA27 is a reversible 
inhibitor while time-dependency experiments 
excluded the possibility to have a tight binder 
of FAAH (Fig. 5A). 
Figure 4. A1-mode of TPA5 refined after 100 ns of MD. 
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Reaction condictions. (i) CH₃OH, H+, reflux; (ii) CH₃OH, aq. HCl, 
Fe, reflux; (iii) CH₃CN, reflux; (iv) DMF-DMA, PhMe, reflux; (v) 
DMF, NH₄Oac, reflux; (vi) aq. NaOH , reflux; (vii) CH₃CN, EDCI, 
HOBt, r.t. 
Scheme 1. Synthetic procedure for TPA series.	  
The2-arylpropionamides were tested for 
their inhibitory activity against FAAH 
using [3H]AEA as substrate. 
Conclusions 
Replacing of the isobutyl group of Ibu-AM5 
with a trifluoromethylpyridinamino moiety 
led TPA5 that maintains the FAAH inhibitory 
activity and shows pure competitive 
inhibition kinetic. 
 
Computational studies, exploiting QM/MM 
and free energy approaches, allowed us to 
identify the binding mode of TPA5 in a cavity 
experimentally found for other competitive 
inhibitors. 
 
Among TPA5 derivatives, the compound 
TPA27 exhibited a 10-fold enhancement in 
the inhibitory profile against FAAH and is the 
first non-competitive reversible FAAH 
inhibitor. Kinetic experiments highlighted 
how small substitutions in the compounds 
belonging to the series of TPA derivatives, 
should dramatically affect the inhibition 
mechanism and binding preferences of these 
inhibitors.  
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Table 2. TPA series inhibition data. aInhibition of 2 mmol·L-1 AEA 
hydrolysis in rat brain homogenates.	  
Scheme 2. The thermodynamic cycle used to compute the difference in 
binding free energy between TPA5 (ligand A) and TPA27 (ligand B).  
FAAH inhibition 
Compound R Ar Max 
inhibition % 
IC50 (µM) 
TPA5	   CH3	   100	   0.59	  
TPA8	   CH3	   100	   23.0	  
TPA9	   CH3	   100	   32.0	  
TPA11	   CH3	   68±4	   11.0	  
TPA12	   CH3	   100	   4.0	  
TPA13	   CH3	   93±3	   12.0	  
TPA19	   CH3	   75±7	   4.3	  
TPA24	   CH3	   100	   0.13	  
TPA25	   CH3	   100	   0.10	  
TPA26	   CH3	   100	   0.33	  
TPA27	   CH3	   100	   0.058	  
DOCKING MD analysis 
ligand mode Pop% AD score MMGBSA cl Pop% Time (ns) MMGBSA MMPBSA SIE QM/MM 
TPA5 
A1 50 -9,11 -59,46 0  97,8 95-100 -58,47 -15,76 -10,21 -78,05 
A2 30 -8,41 -49,65 a0 96,2 95-100 -48,04 -2,46 -9,29 -70,66 
b0 38,6 95-100 -48,64 5,26 -9,39 
B1 9 -9,01 -49,18 a0 66,7 95-100 -45,79 3,03 -8,91 -59,25 
b0 75,1 95-100 -48,23 -2,65 -9,13 
B2 3 -8,67 -50,68 a0 94,5 95-100 -42,41 3,00 -8,62 -63,6 
b0 48,7 95-100 -47,63 1,13 -9,29 
